FWD 1509
Alternative Names: FWD 1509 MsOH; FWD-1509Latest Information Update: 15 Oct 2021
Price :
$50 *
At a glance
- Originator Shenzhen Forward Pharmaceutical
- Developer Shenzhen Forward Pharmaceutical; WuXi Clinical
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 23 Aug 2021 Phase-I/II clinical trials in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT05068024)
- 19 Aug 2021 CDE of the National Food and Drug Administration of China approves FWD 1509 for clinical use for the treatment of Non-small cell lung cancer in China
- 19 Aug 2021 Shenzhen Forward Pharmaceutical plans a phase I trial for Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO)